Premium
Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double‐blind, baseline‐controlled trial
Author(s) -
Schrempf W.,
Fauser M.,
Wienecke M.,
Brown S.,
Maaß A.,
Ossig C.,
Otto K.,
Brandt M. D.,
Löhle M.,
Schwanebeck U.,
Graehlert X.,
Reichmann H.,
Storch A.
Publication year - 2018
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.13567
Subject(s) - rasagiline , polysomnography , epworth sleepiness scale , medicine , modafinil , parkinson's disease , placebo , sleep (system call) , sleep onset , clinical trial , physical therapy , anesthesia , insomnia , disease , psychiatry , apnea , alternative medicine , pathology , computer science , operating system
Background and purpose The aim was to study the effects of rasagiline on sleep quality in patients with Parkinson's disease (PD) with sleep disturbances. Sleep disorders are common in PD. Rasagiline is widely used in patients with PD, but double‐blind polysomnographic trials on its effects on sleep disturbances are missing. Methods This was a single‐center, double‐blind, baseline‐controlled investigator‐initiated clinical trial of rasagiline (1 mg/day) over 8 weeks in patients with PD with sleep disturbances. Blinding was achieved by running a strategic matched placebo parallel group. Co‐primary outcome measures were the changes between baseline and end of the treatment period in sleep maintenance/efficiency as assessed by polysomnography and the Parkinson's Disease Sleep Scale Version 2 (PDSS‐2) score. Results A total of 20 of 30 patients were randomized to rasagiline (mean ± SD age, 69.9 ± 6.9 years; 10 male; Hoehn–Yahr stage, 1.9 ± 0.8). Compared with baseline, sleep maintenance was significantly increased at the end of the treatment period (relative change normalized to baseline, +16.3 ± 27.9%; P = 0.024, paired two‐sided t ‐test) and a positive trend for sleep efficiency was detected (+12.1 ± 28.6%; P = 0.097). Treatment with rasagiline led to significantly decreased wake time after sleep onset, number of arousals, percentage of light sleep and improved daytime sleepiness as measured by the Epworth Sleepiness Scale. We did not observe changes in the co‐primary endpoint PDSS‐2 score, and no correlations of polysomnographic sleep parameters or PDSS‐2 score with motor function (Unified Parkinson's Disease Rating Scale motor score). Rasagiline was well tolerated with no unexpected adverse events. Conclusions In patients with PD with sleep disturbances, rasagiline showed beneficial effects on sleep quality as measured by polysomnography. These effects were probably not related to motor improvement or translated into improved overall sleep quality perception by patients.